The company's growth has not been without conflict. As of September 2013, the number had expanded to 148 stores, including 9 in Washington state. By October 2009, the company had 100 stores in Arizona and California. The company was founded in January 1994 as Beverages & More! in the San Francisco Bay Area, and re-branded as "BevMo!" in January 2001. Previously BevMo! was a privately held corporation based in Concord, California. It is a wholly-owned subsidiary of GoPuff, after GoPuff announced the acquisition of BevMo! on November 5, 2020. John Laird, Medical Director of the Adventist Heart and Vascular Institute.BevMo! is an American retail chain focusing on the sale of alcoholic drinks. The excellent safety profile combined with extremely low need for repeat procedures make this a very promising alternative for our patients with complex vascular disease,” said SAB member Dr. “I have been extremely impressed with the results with the B-Laser Atherectomy System demonstrated in the clinical trials. John Rundback, Interventional Radiologist and Director of the Interventional Institute at Holy Name Medical Center, Teaneck, NJ. “I used the B-Laser in challenging procedures during the pivotal study and found the device easy to set up and use, and a valuable addition to our treatment portfolio,” said the national PI, Dr. In the pilot clinical study, the results presented 100% success in crossing the target with no device-related perioperative clinically significant adverse events and no complications requiring intervention. We are also developing an add-on diagnostic tool and disruptive medical device for interventional gastrointestinal procedures.”Ĭlinical evaluation of the B-Laser™ device in the intended population was performed in a prospective, single-arm, multi-center, open-label, non-randomized pilot clinical study in 50 subjects in Europe, as well as in a pivotal, prospective, single-arm, multi-center, open-label, non-randomized IDE clinical study in 97 subjects in the US and Europe. “We also plan to leverage our B-Laser technology to develop additional devices to address significant unmet needs in other vascular indications, including lead extraction, CAD, Thrombectomy and Venous Disease. This is the first 355nm laser system cleared in the US for this purpose and, according to the clinical results and the feedback that we received from physicians, it seems that this wavelength provides significant advantages over traditional 308nm excimer lasers in term of safety, efficacy, cost and ease of use. Yoel Zabar, CEO of Eximo Medical, commented, “This clearance represents a significant milestone for Eximo, as we can now offer the B-Laser Atherectomy System for PAD in the US. “The enrollment in both US and Europe was quick (6.5 months), and the study results up to six months have been very impressive despite treating diverse lesions such as calcium, thrombus, and restenosis including ISR, both above and below the knee.” The specific indication now approved by the FDA is: “The B-Laser Atherectomy System is intended for use in the treatment, including atherectomy, of infrainguinal stenoses and occlusion, including in-stent restenosis. The B-Laser is described as “a transformative 355nm wavelength laser technology designed to address unmet clinical needs for treating multiple vascular indications.” Eximo Medical, based in Rehovot, Israel, has received 510(k) clearance from the US Food & Drug Administration (FDA) for its B-Laser™ Atherectomy System for Peripheral Artery Disease (PAD). Laser system treats Peripheral Artery Diseases including ISR.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |